EPRX
Income statement / Annual
Last year (2025), Eupraxia Pharmaceuticals Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Eupraxia Pharmaceuticals Inc's net income was -$53.86 M.
See Eupraxia Pharmaceuticals Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$331.89 K
|
$163.47 K
|
$0.00
|
$0.00
|
$112.38 K
|
$117.07 K
|
$207.44 K
|
$125.43 K
|
$86.62 K
|
| Gross Profit |
-$331.89 K
|
-$163.47 K
|
$0.00
|
$0.00
|
-$112.38 K
|
-$117.07 K
|
-$207.44 K
|
-$125.43 K
|
-$86.62 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$29.51 M
|
$16.07 M
|
$15.33 M
|
$13.63 M
|
$7.59 M
|
$1.09 M
|
$3.52 M
|
$6.80 M
|
$3.36 M
|
| General & Administrative Expenses |
$17.10 M
|
$10.92 M
|
$5.63 M
|
$3.99 M
|
$6.97 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$17.10 M
|
$10.92 M
|
$5.63 M
|
$3.99 M
|
$6.97 M
|
$1.27 M
|
$3.10 M
|
$5.10 M
|
$1.48 M
|
| Other Expenses |
$6.72 M
|
$0.00
|
$0.00
|
$0.00
|
$87.47 K
|
$0.00
|
$1.74 K
|
$0.00
|
$0.00
|
| Operating Expenses |
$53.33 M
|
$26.99 M
|
$20.97 M
|
$17.62 M
|
$14.65 M
|
$2.36 M
|
$6.62 M
|
$11.90 M
|
$4.84 M
|
| Cost And Expenses |
$53.66 M
|
$26.99 M
|
$20.97 M
|
$17.62 M
|
$14.65 M
|
$2.47 M
|
$6.82 M
|
$12.02 M
|
$4.93 M
|
| Interest Income |
$1.41 M
|
$1.16 M
|
$649.75 K
|
$431.80 K
|
$51.55 K
|
$427.00
|
$12.04 K
|
$1.11 K
|
$330.00
|
| Interest Expense |
$0.00
|
$603.17 K
|
$881.05 K
|
$982.86 K
|
$1.02 M
|
$1.88 M
|
$1.46 M
|
$142.17 K
|
$52.81 K
|
| Depreciation & Amortization |
$331.89 K
|
$171.60 K
|
$117.10 K
|
$147.89 K
|
$87.47 K
|
$117.07 K
|
$207.44 K
|
$125.43 K
|
$86.62 K
|
| EBITDA |
-$53.33 M |
-$24.95 M |
-$20.78 M |
-$17.86 M |
-$17.22 M |
-$2.02 M |
-$5.73 M |
-$14.52 M |
-$4.93 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$212.94 K
|
$1.26 M
|
-$814.93 K
|
-$1.37 M
|
-$3.68 M
|
-$1.55 M
|
-$615.22 K
|
-$2.76 M
|
-$145.22 K
|
| Income Before Tax |
-$53.87 M
|
-$25.73 M
|
-$21.78 M
|
-$18.99 M
|
-$18.33 M
|
-$4.02 M
|
-$7.44 M
|
-$14.79 M
|
-$5.07 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$26.65 K
|
$1.80 K
|
$27.42 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$53.86 M
|
-$25.49 M
|
-$21.25 M
|
-$18.49 M
|
-$18.03 M
|
-$4.01 M
|
-$7.37 M
|
-$13.19 M
|
-$4.38 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1.05 |
-0.76 |
-0.88 |
-0.96 |
-1.63 |
-0.31 |
-0.56 |
-1.03 |
-0.34 |
| EPS Diluted |
-1.05 |
-0.76 |
-0.88 |
-0.96 |
-1.63 |
-0.31 |
-0.56 |
-1.03 |
-0.34 |
| Weighted Average Shares Out |
$39.96 M
|
$33.93 M
|
$24.15 M
|
$19.29 M
|
$14.24 M
|
$12.87 M
|
$12.87 M
|
$12.87 M
|
$12.87 M
|
| Weighted Average Shares Out Diluted |
$39.96 M
|
$33.93 M
|
$24.15 M
|
$19.29 M
|
$14.24 M
|
$12.87 M
|
$12.87 M
|
$12.87 M
|
$12.87 M
|
| Link |
|
|
|
|
|
|
|
|
|
